NCT04388709View on ClinicalTrials.gov

Interferon Lambda Therapy for COVID-19

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 30, 2020

Primary Completion Date

February 5, 2021

Study Completion Date

February 5, 2021

Conditions

SARS-CoV-2

Interventions

DRUG

Peginterferon Lambda-1A

Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once

Sponsors

Collaborators (1)

Eiger BioPharmaceuticals

All Listed Sponsors

collaborator

Eiger BioPharmaceuticals

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT04388709 - Interferon Lambda Therapy for COVID-19 | Biotech Hunter | Biotech Hunter